证券代码：600513 证券简称：联环药业 公告编号：2026-009 增资标的名称：联环药业（安庆）有限公司 增资金额：以自有及自筹资金增资 5,000.00 万元人民币。 本次增资不涉及关联交易，亦不构成重大资产重组，无需提交公司股东会 审议。 本次增资对象为公司的全资子公司，整体风险可控，但仍受宏观经济、行 业环境、市场竞争等多种因素的影响，其经营状况和收益存在不确定性。同时本 次增资尚需获得国资有权部门审批通过，存在不确定性。公司将加强对联环（安 庆）的运营管理和风险管控，确保其合规、稳健、高效经营。敬请广大投资者理 性投资，注意投资风险。 一、增资情况概述 （一）增资的基本情况 江苏联环药业股份有限公司 关于对全资子公司增资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （1）本次交易概况 为实现江苏联环药业股份有限公司（全文简称"公司"）整体战略目标，为 支持全资子公司联环药业（安庆）有限公司（全文简称"联环（安庆）"）实施其 战略发展规划，满足其在品种研发、批件购买和生产线改扩建等方面的关 ...

Market Performance - The chemical pharmaceutical sector increased by 1.41% on February 3, with Yiming Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Top Gainers in Chemical Pharmaceutical Sector - Yiming Pharmaceutical (002826) closed at 20.98, up 9.27% with a trading volume of 269,200 shares and a transaction value of 559 million [1] - Yuandong Biological (688513) closed at 68.90, up 8.85% with a trading volume of 64,600 shares [1] - Nami Technology (688690) closed at 29.00, up 7.01% with a trading volume of 93,900 shares and a transaction value of 265 million [1] - Lianhuan Pharmaceutical (600513) closed at 20.15, up 5.94% with a trading volume of 162,200 shares and a transaction value of 323 million [1] Top Losers in Chemical Pharmaceutical Sector - Shuangbi Pharmaceutical (002038) closed at 6.41, down 7.10% with a trading volume of 801,300 shares and a transaction value of 511 million [2] - Haizhi Pharmaceutical (002653) closed at 47.50, down 5.47% with a trading volume of 90,200 shares and a transaction value of 430 million [2] - Nuo Cheng Jianhua (688428) closed at 21.13, down 3.78% with a trading volume of 163,500 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 42.01 million from institutional investors, while retail investors saw a net inflow of 651 million [2] - The main capital inflow was observed in Yiming Pharmaceutical with 58.98 million, while it faced a net outflow of 58.77 million from retail investors [3] - Other notable inflows included Guangsheng Tang (300436) with 14.8 million from main capital, while it faced a net outflow of 95.56 million from retail investors [3]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Lidocaine Hydrochloride Gel from the National Medical Products Administration, marking a significant milestone in the company's product development and regulatory compliance [1][4]. Group 1: Drug Registration Certificate Details - The Drug Registration Certificate pertains to Lidocaine Hydrochloride Gel, which is indicated for local anesthesia during procedures requiring such intervention [1]. - The company is one of three domestic enterprises that have obtained this Drug Registration Certificate for the product [1]. - The estimated sales revenue for Lidocaine Hydrochloride Gel in national secondary hospitals and above is approximately 40.86 million yuan in 2024 [1]. Group 2: R&D Investment and Production Approval - As of the announcement date, the cumulative R&D investment for this project is approximately 7.27 million yuan (unaudited) [2]. - This is the first production license obtained by the company in 2026 [3]. Group 3: Impact on the Company - The acquisition of the Drug Registration Certificate for Lidocaine Hydrochloride Gel enhances the company's product line and is expected to improve its market competitiveness [4]. - The impact of this certificate on the company's near-term operating performance is not anticipated to be significant [4].

盐酸利多卡因凝胶适用于局麻药、经尿道施行检查和治疗需局部麻醉者。 截至目前，包括公司在内，国内共有三家企业取得该药品的《药品注册证书》。 2024 年全国二级以上医院盐酸利多卡因凝胶销售额约为 4,086.45 万元（数据 来源于摩熵·医药数据库）。 证券代码：600513 证券简称：联环药业 公告编号：2026-008 江苏联环药业股份有限公司 关于公司获得《药品注册证书》的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的关于盐酸利多卡因凝胶（以 下简称"该药品"）的《药品注册证书》，现将相关情况公告如下： 二、药品的其他情况 1 药品名称 盐酸利多卡因凝胶 剂型 凝胶剂 规格 2%(10g:0.2g) 申请事项 药品注册（境内生产） 注册分类 化学药品 3 类 处方药/非处方药 处方药 受理号 CYHS2402656 证书编号 2026S00232 药品批准文号 国药准字 H20263193 上市许可持有人 名 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Lidocaine Hydrochloride Gel, which is expected to enhance its product line and competitiveness, although it is not anticipated to have a significant impact on recent performance [1] Group 1: Product Approval - The product is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation of generic drug quality and efficacy [1] - The registered specification of the drug is 2% (10g:0.2g) [1] Group 2: Financial Implications - Cumulative R&D investment in this project amounts to approximately 7.27 million yuan [1] - The estimated sales revenue for this product in secondary and higher-level hospitals across the country in 2024 is approximately 40.86 million yuan [1] Group 3: Strategic Impact - The approval of this product is expected to enrich the company's product line and enhance its competitive position in the market [1] - The company anticipates no major impact on its recent performance following this approval [1]

Group 1 - The company announced the progress of an asset purchase and related party transaction involving its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd. [2] - The transaction was approved during the board meeting on September 12, 2025, and the subsequent shareholder meeting on September 30, 2025, with a purchase price of 74.5 million RMB (excluding tax) for certain buildings and land use rights [2] - Lianhuan (Anqing) has paid 50% of the transaction amount and related taxes, and has completed the necessary property rights transfer procedures, obtaining the property certificate from the Anqing Natural Resources and Planning Bureau [3]

江苏联环药业股份有限公司（以下简称"公司"或"联环药业"）于 2025 年 9 月 12 日召开第九届董事会第十五次临时会议，并于 2025 年 9 月 30 日召开 2025 年第三次临时股东会审议通过了《关于全资子公司购买资产暨关联交易的 议案》，同意公司全资子公司联环药业（安庆）有限公司（以下简称"联环（安 庆）"）向公司控股股东江苏联环药业集团有限公司控股孙公司普林斯（安庆）医 药科技有限公司（以下简称"普林斯（安庆）"）以 7,450.00 万元人民币（不含 税）的交易价格购买部分房屋建(构)筑物及土地使用权，具体内容详见披露在上 海证券交易所网站 www.sse.com.cn 的《联环药业第九届董事会第十五次临时会 议决议公告》（公告编号：2025-070）、《联环药业关于全资子公司购买资产暨关 联交易的公告》（公告编号：2025-072）、《联环药业 2025 年第三次临时股东会决 议公告》（公告编号：2025-077）。 二、交易的进展情况 联环（安庆）已按合同要求向普林斯（安庆）支付部分交易款项（50%）及 相关税费缴纳，并完成房屋建（构）筑物及土地使用权的不动产权的变更手续， 近日，联环（ ...

Core Viewpoint - The company announced that the Phase III clinical trial of LH-1801 is expected to unblind in the first quarter of 2026, and there are currently no undisclosed matters that need to be reported [1] Group 1 - The company is actively engaging with investors through an interactive platform, indicating transparency in communication [1] - The company emphasizes the uncertainties associated with innovative drug development, which may impact investment decisions [1] - The company will provide timely updates on any progress related to LH-1801 and encourages investors to monitor relevant announcements [1]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is expected to report a net loss of between 83 million to 99 million yuan for the year 2025, marking its first annual loss since going public, with a year-on-year decline of 217.63% to 198.62% [2][3] Financial Performance - In 2024, the company experienced a slight decline in revenue, achieving 2.16 billion yuan, a decrease of 0.63% year-on-year; net profit attributable to shareholders fell by 37.66% to 84.16 million yuan, while the net profit after deducting non-recurring items dropped by 56.89% to 49.87 million yuan [3] - The projected net loss for 2025 represents a decrease of 166.7 million to 183 million yuan compared to the previous year, with a decline exceeding 200%; the net profit after deducting non-recurring items is expected to be a loss of 32.5 million to 39 million yuan, down by 82.37 million to 88.87 million yuan [3] Regulatory Impact - The company faced a significant antitrust fine of 61.04 million yuan, which directly impacted its net profit; this fine accounted for 72.53% of the audited net profit for 2024 and 2.83% of the annual revenue, leading to a direct reduction of 61.04 million yuan in the projected net profit for 2025 [4] Operational Challenges - The company is under pressure from industry policy adjustments, high R&D costs, and restricted financing channels, which have contributed to its declining performance; the core product's gross margin is under pressure due to national drug procurement policies and increased international market competition [5] - The price of dexamethasone phosphate sodium, a key raw material, has plummeted to between 0.23 yuan and 0.57 yuan per unit post-antitrust penalty, significantly lower than the maximum price of 98.76 yuan during the period of monopoly, compressing the profitability of related businesses [5] R&D and Financing - The company has been increasing its R&D investment significantly, with expenses rising from 66 million yuan in 2021 to 155 million yuan in 2024, averaging over 30% annual growth; however, this sustained investment continues to pressure profit margins [5] - The company has faced challenges in financing, with two failed fundraising attempts in 2024 totaling 7.35 million yuan, which were terminated due to "market environment changes and the company's actual operating conditions"; it has since sought debt financing, applying for a 240 million yuan R&D loan [6] Future Outlook - The company is exploring how to address the profit gap created by the antitrust fine and whether the 240 million yuan R&D loan will be successfully secured; there are concerns regarding its cash flow situation and how it will restructure its core profit segments to achieve profitability [7]

Meeting Summary - The 21st temporary meeting of the 9th Board of Directors of Jiangsu Lianhuan Pharmaceutical Co., Ltd. was held on January 23, 2026, via communication, with all 9 directors present, meeting the requirements of the company's articles of association [2][5]. Board Resolutions - The Board approved the proposal to establish a "Business Isolation System" to enhance risk management and ensure business separation between the company and its affiliated fund management entities, promoting stable and healthy development [3]. Financial Performance Forecast - The company forecasts a net profit attributable to shareholders for 2025 to be in the range of -99 million to -83 million RMB, indicating a decrease of 166.66 million to 183.16 million RMB compared to the previous year [7][9]. - The net profit after deducting non-recurring gains and losses is expected to be between -39 million and -32.5 million RMB, a reduction of 82.37 million to 88.87 million RMB year-on-year [7][9]. Previous Year Performance - In 2024, the net profit attributable to shareholders was 84.16 million RMB, and the net profit after deducting non-recurring gains and losses was 49.87 million RMB, with earnings per share at 0.29 RMB [10][11]. Reasons for Expected Loss - The expected loss is attributed to several factors, including pressure on gross margins from national drug procurement policies, adjustments in medical insurance payment policies, increased international market competition, administrative penalties leading to non-recurring expenses, and rising R&D costs due to increased investment in innovative drug development [11].